SCHEDULE: FMR LLC Discloses Nektar Therapeutics Stake

FMR LLC, through its subsidiaries, has reported beneficial ownership of 15.0% of Nektar Therapeutics' common stock as of March 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson and certain subsidiaries, has filed a Schedule 13G amendment indicating their beneficial ownership of Nektar Therapeutics' common stock.
• The filing, dated March 31, 2026, shows a total of 4,303,188.37 shares beneficially owned, representing 15.0% of the class of securities.
• Fidelity Growth Company Fund holds 1,608,001.00 shares (5.6%), and Fidelity Growth Company Commingled Pool holds 1,861,842.00 shares (6.5%) of Nektar Therapeutics' common stock.
• FMR LLC is classified as a holding company, and Abigail P. Johnson is identified as an individual investor.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing beneficial ownership and does not contain new operational or financial information about Nektar Therapeutics.

Positives

• FMR LLC's significant stake indicates confidence in Nektar Therapeutics' long-term prospects.
• The filing confirms substantial holdings by Fidelity Growth Company Fund and Fidelity Growth Company Commingled Pool, suggesting diversified investment strategies within the Fidelity group.

Negatives

• The filing does not contain any negative financial results or operational challenges for Nektar Therapeutics.

Risks

• The filing does not explicitly mention any current issues or potential future challenges for Nektar Therapeutics.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Nektar Therapeutics' future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."

Industry Context

StockSavvy.ai notes that large institutional investors like FMR LLC filing Schedule 13G amendments often signal significant positions in publicly traded companies, which can be a signal of conviction or a precursor to further activity. For Nektar Therapeutics, this filing indicates continued institutional interest in the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding, which can influence market perception and potentially stock price stability.
• Management of Nektar Therapeutics: Awareness of substantial ownership by major financial institutions is a standard aspect of corporate governance.

Next Steps

• FMR LLC and its associated entities will continue to hold their reported stake in Nektar Therapeutics' common stock.
• Future filings will indicate any changes in beneficial ownership.

Key Dates

Keywords

Nektar Therapeutics, FMR LLC, Schedule 13G, Fidelity Growth Company Fund, Fidelity Growth Company Commingled Pool, Beneficial Ownership, Common Stock, Investment, SEC Filing